Breakthrough Approval: UK Regulator Greenlights Moderna's RSV Vaccine for Seniors
2025-02-28
Reuters
In a significant development, the UK's health regulator has approved Moderna's RSV vaccine for individuals aged 60 and above, offering protection against lower respiratory tract disease caused by the respiratory syncytial virus. This vaccine approval is expected to provide relief to seniors, who are highly susceptible to RSV infections. With this breakthrough, Moderna's vaccine is poised to play a crucial role in preventing RSV-related illnesses, particularly among the elderly population. The vaccine's approval is a major milestone in the fight against respiratory diseases, and its impact is likely to be felt across the healthcare sector, including vaccine development and infectious disease prevention.
